This comprehensive review addresses the critical challenge of managing background wild-type DNA across biomedical research and therapeutic development.
Accurate analysis of fragmented DNA is a critical challenge in fields from forensic science to cancer diagnostics and biotherapeutic safety.
This article provides a comprehensive analysis of droplet generation issues in droplet digital PCR (ddPCR) systems, addressing critical challenges researchers face in achieving reliable, monodisperse droplets for absolute nucleic acid...
The analysis of circulating tumor DNA (ctDNA) has emerged as a transformative tool in oncology, enabling non-invasive cancer diagnosis, treatment selection, and response monitoring.
The analysis of circulating tumor DNA (ctDNA) via PCR-based methods is fundamental to liquid biopsy but is critically limited by PCR inhibition and the ultra-low abundance of target DNA, which...
Hemolysis presents a significant pre-analytical challenge in circulating tumor DNA (ctDNA) testing, potentially compromising assay sensitivity and specificity by releasing wild-type genomic DNA from lysed blood cells.
This article provides a systematic examination of preanalytical variables in liquid biopsy, a critical yet often overlooked factor determining the success of cancer research and precision oncology.
The detection of circulating tumor DNA (ctDNA) is revolutionizing cancer management, but its low abundance in early-stage disease remains a significant challenge.
Digital PCR (dPCR) offers exceptional sensitivity for applications from oncology to infectious disease diagnostics, but its accuracy can be compromised by false positives.
This article comprehensively examines cutting-edge ultrasensitive circulating tumor DNA (ctDNA) detection technologies transforming cancer management.